Modification of human leukocyte interferon pharmacology with a monoclonal antibody

M. G. Rosenblum, B. W. Unger, J. U. Gutterman, Evan M Hersh, G. S. David, J. M. Frincke

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

The antitumor and antiviral properties of the interferons have been well established. However, the usefulness of the interferons may be limited, in part, because of rapid clearance from the plasma and degradation by plasma or tissue enzymes. A monoclonal antibody (IFG-252.2) was developed which binds to recombinant DNA-produced human α-interferon (rIFN-αA) without measurably reducing its in vitro antiviral or antiproliferative properties. Pharmacokinetic studies of rIFN-αA:antibody complex in the intact, anesthetized rat showed that rIFN-αA activity cleared from plasma 3-fold slower than found after injection of free rIFN-αA. This resulted in a 15-fold increase in its calculated area under concentration curve compared to that of free rIFN-αA. These studies suggest that interferon bound to a monoclonal antibody may provide a means to prevent the normal clearance and degradation of free interferon and may result in prolonged antitumor and antiviral plasma activity in vivo. Furthermore, it suggests that monoclonal antibodies to various biologically active agents may be used to favorably alter their pharmacokinetics while leaving their biological activity unaltered.

Original languageEnglish (US)
Pages (from-to)2421-2424
Number of pages4
JournalCancer Research
Volume45
Issue number6
StatePublished - 1985
Externally publishedYes

Fingerprint

Interferon-alpha
Interferons
Monoclonal Antibodies
Pharmacology
Antiviral Agents
Pharmacokinetics
Recombinant DNA
Area Under Curve
Injections
Antibodies
Enzymes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Rosenblum, M. G., Unger, B. W., Gutterman, J. U., Hersh, E. M., David, G. S., & Frincke, J. M. (1985). Modification of human leukocyte interferon pharmacology with a monoclonal antibody. Cancer Research, 45(6), 2421-2424.

Modification of human leukocyte interferon pharmacology with a monoclonal antibody. / Rosenblum, M. G.; Unger, B. W.; Gutterman, J. U.; Hersh, Evan M; David, G. S.; Frincke, J. M.

In: Cancer Research, Vol. 45, No. 6, 1985, p. 2421-2424.

Research output: Contribution to journalArticle

Rosenblum, MG, Unger, BW, Gutterman, JU, Hersh, EM, David, GS & Frincke, JM 1985, 'Modification of human leukocyte interferon pharmacology with a monoclonal antibody', Cancer Research, vol. 45, no. 6, pp. 2421-2424.
Rosenblum MG, Unger BW, Gutterman JU, Hersh EM, David GS, Frincke JM. Modification of human leukocyte interferon pharmacology with a monoclonal antibody. Cancer Research. 1985;45(6):2421-2424.
Rosenblum, M. G. ; Unger, B. W. ; Gutterman, J. U. ; Hersh, Evan M ; David, G. S. ; Frincke, J. M. / Modification of human leukocyte interferon pharmacology with a monoclonal antibody. In: Cancer Research. 1985 ; Vol. 45, No. 6. pp. 2421-2424.
@article{bca6c37d0e7240d68db654bc605a57d4,
title = "Modification of human leukocyte interferon pharmacology with a monoclonal antibody",
abstract = "The antitumor and antiviral properties of the interferons have been well established. However, the usefulness of the interferons may be limited, in part, because of rapid clearance from the plasma and degradation by plasma or tissue enzymes. A monoclonal antibody (IFG-252.2) was developed which binds to recombinant DNA-produced human α-interferon (rIFN-αA) without measurably reducing its in vitro antiviral or antiproliferative properties. Pharmacokinetic studies of rIFN-αA:antibody complex in the intact, anesthetized rat showed that rIFN-αA activity cleared from plasma 3-fold slower than found after injection of free rIFN-αA. This resulted in a 15-fold increase in its calculated area under concentration curve compared to that of free rIFN-αA. These studies suggest that interferon bound to a monoclonal antibody may provide a means to prevent the normal clearance and degradation of free interferon and may result in prolonged antitumor and antiviral plasma activity in vivo. Furthermore, it suggests that monoclonal antibodies to various biologically active agents may be used to favorably alter their pharmacokinetics while leaving their biological activity unaltered.",
author = "Rosenblum, {M. G.} and Unger, {B. W.} and Gutterman, {J. U.} and Hersh, {Evan M} and David, {G. S.} and Frincke, {J. M.}",
year = "1985",
language = "English (US)",
volume = "45",
pages = "2421--2424",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Modification of human leukocyte interferon pharmacology with a monoclonal antibody

AU - Rosenblum, M. G.

AU - Unger, B. W.

AU - Gutterman, J. U.

AU - Hersh, Evan M

AU - David, G. S.

AU - Frincke, J. M.

PY - 1985

Y1 - 1985

N2 - The antitumor and antiviral properties of the interferons have been well established. However, the usefulness of the interferons may be limited, in part, because of rapid clearance from the plasma and degradation by plasma or tissue enzymes. A monoclonal antibody (IFG-252.2) was developed which binds to recombinant DNA-produced human α-interferon (rIFN-αA) without measurably reducing its in vitro antiviral or antiproliferative properties. Pharmacokinetic studies of rIFN-αA:antibody complex in the intact, anesthetized rat showed that rIFN-αA activity cleared from plasma 3-fold slower than found after injection of free rIFN-αA. This resulted in a 15-fold increase in its calculated area under concentration curve compared to that of free rIFN-αA. These studies suggest that interferon bound to a monoclonal antibody may provide a means to prevent the normal clearance and degradation of free interferon and may result in prolonged antitumor and antiviral plasma activity in vivo. Furthermore, it suggests that monoclonal antibodies to various biologically active agents may be used to favorably alter their pharmacokinetics while leaving their biological activity unaltered.

AB - The antitumor and antiviral properties of the interferons have been well established. However, the usefulness of the interferons may be limited, in part, because of rapid clearance from the plasma and degradation by plasma or tissue enzymes. A monoclonal antibody (IFG-252.2) was developed which binds to recombinant DNA-produced human α-interferon (rIFN-αA) without measurably reducing its in vitro antiviral or antiproliferative properties. Pharmacokinetic studies of rIFN-αA:antibody complex in the intact, anesthetized rat showed that rIFN-αA activity cleared from plasma 3-fold slower than found after injection of free rIFN-αA. This resulted in a 15-fold increase in its calculated area under concentration curve compared to that of free rIFN-αA. These studies suggest that interferon bound to a monoclonal antibody may provide a means to prevent the normal clearance and degradation of free interferon and may result in prolonged antitumor and antiviral plasma activity in vivo. Furthermore, it suggests that monoclonal antibodies to various biologically active agents may be used to favorably alter their pharmacokinetics while leaving their biological activity unaltered.

UR - http://www.scopus.com/inward/record.url?scp=0021883056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021883056&partnerID=8YFLogxK

M3 - Article

C2 - 3986783

AN - SCOPUS:0021883056

VL - 45

SP - 2421

EP - 2424

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 6

ER -